Experienced in POEMS Syndrome

Dr. Hans C. Lee

Hematology | Oncology
Verdi Oncology Tennessee PC
335 24th Ave N, Suite 200, 
Nashville, TN 
Offers Telehealth
Experienced in POEMS Syndrome
Verdi Oncology Tennessee PC
335 24th Ave N, Suite 200, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hans Lee is a Hematologist and an Oncologist in Nashville, Tennessee. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of POEMS Syndrome. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 142 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of POEMS Syndrome.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MO
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

VERDI ONCOLOGY TENNESSEE PC
335 24th Ave N, Suite 200, Nashville, TN 37203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Study of Daratumumab, Bortezomib, and Dexamethasone (DVd), Followed by Daratumumab, Ixazomib, and Dexamethasone (DId) for Relapsed and/or Refractory Myeloma
A Phase 2 Study of Daratumumab, Bortezomib, and Dexamethasone (DVd), Followed by Daratumumab, Ixazomib, and Dexamethasone (DId) for Relapsed and/or Refractory Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Bortezomib, Daratumumab, Dexamethasone, Ixazomib
Study Phase: Phase 2
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Biological, Drug
Study Drugs: Daratumumab, Dexamethasone, Ixazomib
Study Phase: Phase 1
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Procedure, Drug
Study Drugs: Carfilzomib, Dexamethasone, Dexamethasone Sodium Phosphate, Lenalidomide, MDM2 Inhibitor KRT-232
Study Phase: Phase 1
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

142 Total Publications

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.
Journal: American journal of hematology
Published: July 30, 2025
Similar Doctors
Advanced in POEMS Syndrome
Dr. Adam C. Seegmiller
Hematology
Advanced in POEMS Syndrome
Dr. Adam C. Seegmiller
Hematology

Vanderbilt University Medical Center

1301 22nd Ave S, 
Nashville, TN 
 (0.9 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Adam Seegmiller is a Hematologist in Nashville, Tennessee. Dr. Seegmiller is rated as a Distinguished provider by MediFind in the treatment of POEMS Syndrome. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Seegmiller is currently accepting new patients.

Experienced in POEMS Syndrome
Dr. Jamal G. Maatouk
Oncology | Hematology
Experienced in POEMS Syndrome
Dr. Jamal G. Maatouk
Oncology | Hematology

Tennessee Oncology PLLC

2004 Hayes St, Suite 350, 
Nashville, TN 
 (0.6 miles away)
615-312-3333
Languages Spoken:
English, Arabic, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Jamal Maatouk is an Oncologist and a Hematologist in Nashville, Tennessee. Dr. Maatouk is rated as a Distinguished provider by MediFind in the treatment of POEMS Syndrome. Her top areas of expertise are Thrombocytopenia, Paget Disease of the Breast, Adult Immune Thrombocytopenia, and Hemangioma Thrombocytopenia Syndrome. Dr. Maatouk is currently accepting new patients.

Experienced in POEMS Syndrome
Dr. Lindsey M. Goodman
Hematology Oncology | Hematology | Oncology
Experienced in POEMS Syndrome
Dr. Lindsey M. Goodman
Hematology Oncology | Hematology | Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (0.9 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lindsey Goodman is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Goodman is rated as an Advanced provider by MediFind in the treatment of POEMS Syndrome. Her top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Multiple Myeloma, Lung Cancer, and Small Cell Lung Cancer (SCLC). Dr. Goodman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile